What is it about?

The novel ultra-rapid-acting insulins provide additional bolus insulin options, and their quick onset of action provides additional dosing flexibility for patients with type 1 and 2 diabetes. Due to comparable efficacy and safety amongst other quick-acting insulin agents, healthcare providers should engage in shared decision making with the patient and family members while taking into account the patient’s preferences, considerations, and insurance formulary coverage.

Featured Image

Read the Original

This page is a summary of: Ultra-Rapid-Acting Insulins: How Fast Is Really Needed?, Clinical Diabetes, October 2021, American Diabetes Association,
DOI: 10.2337/cd20-0119.
You can read the full text:

Read

Contributors

Be the first to contribute to this page